Biohaven (NASDAQ: BHVN) director reports gifting 34,684 shares, adds family trust

Rhea-AI Filing Summary

Biohaven Ltd. director Kishan Mehta reported bona fide gift transfers of a total of 34,684 common shares on 2026-03-17. One transfer of 17,342 shares reduced his directly held stake to 5,320 common shares.

A separate 17,342-share transfer is shown as indirectly held by the “Kishen Mehta 21 Family Irrevocable Trust.” The trust is for the benefit of family members other than the reporting person, and Mehta disclaims beneficial ownership of the securities held by the trust.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mehta Kishan

(Last) (First) (Middle)

C/O BIOHAVEN LTD.

215 CHURCH STREET

(Street)

NEW HAVEN CONNECTICUT 06510

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Biohaven Ltd. [ BHVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/17/2026		G		17,342	D	$0	5,320	D
Common Shares	03/17/2026		G		17,342	A	$0	17,342	I	By Kishen Mehta 21 Family Irrevocable Trust(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These Common Shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse and the spouse's sibling are co-trustees of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Remarks:

	/s/ George Clark, Attorney-in-Fact	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Biohaven (BHVN) director Kishan Mehta report?

Biohaven director Kishan Mehta reported bona fide gift transfers of common shares. On 17 March 2026, disclosures show two gift transactions totaling 34,684 common shares, rather than open‑market buying or selling activity.

How many Biohaven (BHVN) shares were gifted in the latest insider report?

The report shows gifts totaling 34,684 Biohaven common shares. One 17,342‑share gift reduced the director’s directly held position, and another 17,342‑share block is attributed to a family irrevocable trust.

What is Kishan Mehta’s direct Biohaven (BHVN) shareholding after the gifts?

After the 17,342‑share gift disposition, Kishan Mehta directly holds 5,320 Biohaven common shares. This figure reflects only his direct ownership and excludes any securities attributed to family trusts.

How are the Biohaven (BHVN) shares held by the family trust treated in the disclosure?

The 17,342 Biohaven common shares are held by the “Kishen Mehta 21 Family Irrevocable Trust.” The trust benefits family members other than the director, and he expressly disclaims beneficial ownership of those securities.

Was there any sale price for the Biohaven (BHVN) insider transactions?

No sale price is shown because the transactions are bona fide gifts at a per‑share price of $0.00. This indicates value was transferred without consideration, rather than through an open‑market sale.